David M. Routman
Papers
3
Total Citations
73
H-Index
3
About
David M. Routman is a leading radiation oncologist whose research focuses on de-escalating treatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) without compromising outcomes. His most impactful work includes the landmark Phase III trial MC1675, which evaluated De-Escalated Adjuvant Radiation Therapy (DART) versus standard adjuvant treatment for HPV-positive OPSCC, accumulating 53 citations. Routman has also contributed to understanding postoperative morbidity and mortality following transoral robotic surgery through retrospective analyses of prospective de-escalation trials (MC1273 & MC1675), cited 16 times. His recent work on circulating tumor HPV DNA (ctHPVDNA) kinetics after surgery—published in 2025—explores a critical biomarker for disease presence and clearance, offering new insights into early postoperative monitoring. With a growing citation impact and a focus on reducing treatment burden while maintaining efficacy, Routman is shaping the future of personalized, de-escalated therapy for HPV-associated head and neck cancers. His contributions are particularly relevant for clinicians and researchers seeking to balance oncologic control with quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3